Table 3.
Pathogenic alterations in primary tumors and their cutaneous metastasis.
| Surrogate Molecular Types | Gene | Primary Tumors n (%) |
Cutaneous Metastases n (%) |
|
|---|---|---|---|---|
| TN n = 12 |
Mutations | TP53 | 10 (83) | 11 (92) |
| PIK3CA | 2 (17) | 4 (33) | ||
| NF1 | 1 (8.3) | 1 (8.3) | ||
| TN n = 7 |
CNVs | MYC | 1 (14.3) | 3 (42.9) |
| MDM4 | 0 | 1 (14.3) | ||
| FGFR1 | 1 (14.3) | 1 (14.3) | ||
| Luminal HER2- n = 16 |
Mutations | TP53 | 1 (6) | 1 (6) |
| PIK3CA | 7 (39) | 7 (39) | ||
| NF1 | 1 (6.2) | 2 (12.5) | ||
| AKT1 | 2 (12.5) | 2 (12.5) | ||
| Luminal HER2- n = 9 |
CNVs | MYC | 1 (11.1) | 1 (11.1) |
| MDM4 | 0 | 1 (11.1) | ||
| CCND1 | 1 (11.1) | 0 | ||
| HER2+ n = 5 |
Mutations | TP53 | 2 (40) | 2 (40) |
| PIK3CA | 4 (80) | 4 (80) | ||
| NF1 | 1 (20) | 1 (20) | ||
| AKT1 | 1 (20) | 1 (20) | ||
| HER2+ n = 4 |
CNVs | MYC | 1 (25) | 1 (25) |
| MDM4 | 0 | 1 (25) | ||
| FGFR1 | 1 (25) | 1 (25) | ||
| CCND1 | 0 | 1 (25) |